share_log

Jin Medical International Ltd. Announces Exercise of the Underwriters' Over-Allotment Option

Jin Medical International Ltd. Announces Exercise of the Underwriters' Over-Allotment Option

Jin Medical International Ltd.宣佈行使承銷商的超額配股權
GlobeNewswire ·  2023/04/06 22:40

Changzhou City, China, April 06, 2023 (GLOBE NEWSWIRE) -- Jin Medical International Ltd. (the "Company" or "JinMed") (NASDAQ: ZJYL), a Cayman Islands holding company with Chinese operating entities that manufacture and develop wheelchairs and living aids products, today announced that Prime Number Capital, LLC, as the representative of the underwriters of the Company's initial public offering ("IPO"), has partially exercised the over-allotment option to purchase an additional 47,355 ordinary shares at the IPO price of $8.00 per share. As a result, the Company has raised gross proceeds of $378,840, in addition to the previously announced IPO gross proceeds of $8,000,000, before deducting underwriting discounts and offering expenses.

中國常州市,2023年4月6日(GLOBE NEWSWIRE)——開曼羣島控股公司Jin Medical International Ltd(“公司” 或 “JinMed”)(納斯達克股票代碼:ZJYL)今天宣佈,作爲公司首次公開募股(“IPO”)承銷商代表的Prime Number Capital, LLC已部分行使超額行使以每股8.00美元的IPO價格額外購買47,355股普通股的配股權。因此,在扣除承保折扣和發行費用之前,除了先前宣佈的8,000,000,000美元的首次公開募股總收益外,公司還籌集了378,840美元的總收益。

Prime Number Capital, LLC acted as the sole bookrunner for the IPO. SBI China Capital Financial Services Limited acted as the co-manager for the IPO. Hunter Taubman Fischer & Li LLC acted as counsel to the Company, and Kaufman & Canoles, P.C. acted as counsel to the underwriters.

Prime Number Capital, LLC是首次公開募股的唯一賬簿管理人。SBI中國資本金融服務有限公司擔任首次公開募股的聯席經理。Hunter Taubman Fischer & Li LLC擔任該公司的法律顧問,Kaufman & Canoles, P.C. 擔任承銷商的法律顧問。

A registration statement on Form F-1 (File No. 333-259767) relating to the IPO, as amended, has been filed with the Securities and Exchange Commission (the "SEC") and was declared effective by the SEC on March 27, 2023. The IPO was being made only by means of a prospectus. Copies of the final prospectus related to the IPO may be obtained from Prime Number Capital, LLC by email at info@pncps.com. In addition, a copy of the final prospectus can also be obtained via the SEC's website at www.sec.gov.

經修訂的與首次公開募股有關的F-1表格(文件編號333-259767)的註冊聲明已提交給美國證券交易委員會(“SEC”),並由美國證券交易委員會於2023年3月27日宣佈生效。首次公開募股僅通過招股說明書進行。與首次公開募股有關的最終招股說明書的副本可通過電子郵件從Prime Number Capital, LLC獲得,電子郵件地址爲 info@pncps.com。此外,最終招股說明書的副本也可以通過美國證券交易委員會的網站www.sec.gov獲得。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

本新聞稿不構成出售要約或招攬購買本文所述證券的要約,在根據任何此類州或司法管轄區的證券法進行註冊或資格認證之前,此類要約、招標或出售是非法的州或司法管轄區也不得出售這些證券。

About Jin Medical International Ltd.

關於 金醫療國際有限公司

Founded in 2006 and headquartered at Changzhou City, Jiangsu Province of China, the Company, through its Chinese operating entities, designs and manufactures wheelchairs and living aids products for people with disabilities, the elderly, and people recovering from injuries. The Company's Chinese operating entities operate 2 manufacturing plants with approximately 228,257 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. The Company's Chinese operating entities have established relationships with over 40 distributors in China, and over 20 in the other regions of the world where it currently sells the products. The majority of its wheelchair products, with more than 30 models, are sold to dealers in Japan and China, including Nissin Medical Industries Co., Ltd, one of the largest medical device distributors in Japan. The Company's Chinese operating entities own 106 patents and are in the process of registering 22 additional patents with the Patent Administration Department of the People's Republic of China and continuously deliver innovative wheelchair designs that are both lightweight and ergonomic each year. For more information, please visit: .

該公司成立於 2006 年,總部位於中國江蘇省常州市,通過其中國運營實體爲殘疾人、老年人和受傷康復者設計和製造輪椅和生活輔助產品。該公司的中國運營實體在中國江蘇省常州市和泰州市經營兩座製造工廠,總面積約爲228,257平方英尺。該公司的中國運營實體已與中國的40多家分銷商建立了關係,並在其目前銷售產品的世界其他地區的20多家分銷商建立了關係。其大多數輪椅產品有30多種型號,銷往日本和中國的經銷商,包括日本最大的醫療器械分銷商之一日信醫療工業株式會社。該公司的中國運營實體擁有106項專利,並且正在向中華人民共和國專利管理部另外註冊22項專利,並且每年持續提供既輕巧又符合人體工程學的創新輪椅設計。欲瞭解更多信息,請訪問: 。

Forward-Looking Statement

前瞻性陳述

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company's statements regarding the expected trading of its Ordinary Shares on the Nasdaq Capital Market and the closing of the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the "Risk Factors" section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

本新聞稿包含前瞻性陳述。前瞻性陳述包括有關計劃、目標、目標、戰略、未來事件或績效的陳述,以及除歷史事實陳述以外的基本假設和其他陳述。當公司使用 “可能、“將”、“打算”、“應該”、“相信”、“期望”、“預期”、“項目”、“估計” 等詞語或與歷史問題無關的類似表達方式時,它是在發表前瞻性陳述。 這些前瞻性陳述包括但不限於 公司關於以下內容的聲明 預期的 交易 它的 普通股 納斯達克資本市場發行結束。前瞻性陳述不能保證未來的業績,涉及風險和不確定性,可能導致實際業績與前瞻性陳述中討論的公司預期存在重大差異。這些陳述受不確定性和風險的影響,包括但不限於 與市場狀況和按預期條件完成首次公開募股有關的不確定性,以及向公司提交的註冊聲明的 “風險因素” 部分中討論的其他因素 。出於這些原因,除其他外,提醒投資者不要過分依賴本新聞稿中的任何前瞻性陳述。公司向美國證券交易委員會提交的文件中討論了其他因素,這些文件可在以下網址進行審查 www.sec.gov。公司沒有義務公開修改這些前瞻性陳述,以反映本陳述發佈之日之後發生的事件或情況。

For more information, please contact:

欲瞭解更多信息,請聯繫:

Underwriters

承銷商s

Prime Number Capital LLC

素數資本有限責任公司

Ms. Xiaoyan Jiang, Chairwoman

董事長姜曉燕女士

Email:xj@pncps.com

電子郵件:xj@pncps.com

Phone: 516-582-9666

電話:516-582-9666

Investor Relations

投資者關係

Wealth Financial Services LLC

財富金融服務有限責任公司

Janice Wang

王珍妮

Email: services@wealthfsllc.com

電子郵件: services@wealthfsllc.com

Phone: +86 13811768599

電話:+86 13811768599

+1 628 283 9214

+1 628 283 9214


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論